Taysha Gene Therapies (TSHA) Change in Accured Expenses (2020 - 2026)

Taysha Gene Therapies has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$5.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.1 million, down 142.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 182.28% YoY), and the FY2025 annual result was $6.3 million, up 542.58% from the prior year.
• Change in Accured Expenses came in at -$5.1 million for Q1 2026 at Taysha Gene Therapies, down from $2.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q3 2025 to a low of -$7.7 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is -$747000.0 (2022), against an average of -$934176.5.
• Across the five-year window, Change in Accured Expenses tumbled 2453.04% in 2023 and surged 2422.64% in 2025, its largest moves.
• Taysha Gene Therapies' Change in Accured Expenses stood at -$747000.0 in 2022, then tumbled by 170.01% to -$2.0 million in 2023, then surged by 105.26% to $106000.0 in 2024, then soared by 2422.64% to $2.7 million in 2025, then tumbled by 292.56% to -$5.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.1 million (Q1 2026), $2.7 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.